BAX▲
Baxter Upsizes Cash Tender Offers to $600 Million
Baxter International announced early tender results and increased the aggregate purchase price cap for its cash tender offers from $500 million to $600 million. As of the early tender time on August 17, 2026, holders had validly tendered $421,990,000 of the 3.132% Senior Notes due 2051, $132,199,000 of the 3.500% Senior Notes due 2046, $72,744,000 of the 4.500% Senior Notes due 2043, and $756,712,000 of the 2.539% Senior Notes due 2032. The company will accept notes using a waterfall methodology up to the new $600 million cap, with an early tender premium of $30 per $1,000 principal amount included in the total consideration. The early settlement date is August 20, 2026, and BofA Securities, J.P. Morgan Securities, and Goldman Sachs are acting as lead dealer managers.
Business Wire·8dRead more ▾
BAX▼
West Pharmaceutical Stock Surges 38.1% on Strong HVP Demand
West Pharmaceutical Services stock has surged 38.1% since the end of March, far outpacing its industry's 9% gain and the S&P 500's 18.6% growth. The rally is supported by a sharp improvement in operating momentum, with the company delivering 13% organic revenue growth and 29% adjusted earnings per share growth in the second quarter. Management raised its 2026 outlook to 10-11% organic revenue growth, driven by strong demand for high-value proprietary products used in biologics and GLP-1 therapies. Proprietary Products grew 16% organically, Biologics jumped 29%, and HVP Components increased 18.4% to represent 49% of revenues. The company also benefits from Annex 1 upgrades, GLP-1 demand expansion, and a 29% organic surge in HVP Delivery Devices, while competitors Baxter, Becton Dickinson, and AptarGroup posted slower growth.
Zacks Investment Research·12dRead more ▾
BAX▲
Regeneron and DexCom lead healthcare sector in July as Moderna and managed-care stocks retreat
The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.
Seeking Alpha·25dRead more ▾
BAX▲
Baxter International Stock Surges 19% After Earnings Beat and Raised Guidance
Baxter International shares jumped 19% this week after the medical device company reported second-quarter results that beat analyst estimates and raised its full-year guidance. Revenue rose 5% to $2.96 billion, with U.S. sales up 4% to $1.6 billion and international sales up 7% to $1.4 billion, while adjusted earnings per share came in at $0.56, well above the $0.37 consensus. Management now expects full-year sales growth of 3% to 4%, up from a prior forecast of flat to 1%, and adjusted EPS of $1.95 to $2.15, compared with the earlier range of $1.85 to $2.05. The company’s medical products and therapies segment grew 7% to nearly $2.1 billion, and healthcare systems and technologies rose 4% to $801 million.
The Motley Fool·26dRead more ▾
Baxter Reports Upbeat Q2 CY2026 Results, Stock Jumps 16.1%
Baxter International reported second-quarter CY2026 results that exceeded market revenue expectations, with sales rising 5.3% year on year to $2.96 billion. The company's non-GAAP profit of $0.56 per share was 52.5% above analysts' consensus estimates. Adjusted operating income reached $421 million, beating estimates by 37.9%, and management raised its full-year adjusted EPS guidance to $2.05 at the midpoint, a 5.1% increase. The stock traded up 16.1% to $28.74 immediately after the announcement.
Yahoo Finance·27dRead more ▾
BAX
Baxter International to Report Earnings Thursday Before Market Open
Baxter International will report its quarterly earnings this Thursday before the market opens. The company beat revenue expectations last quarter with $2.70 billion, up 2.9% year on year, and also exceeded analysts' EPS and full-year EPS guidance estimates. For the upcoming report, the market expects flat revenue year on year, a slowdown from the 4.3% growth in the same quarter last year. Analysts have largely maintained their estimates over the past 30 days, though Baxter has missed revenue estimates multiple times in the last two years. Peers Abbott Laboratories and Intuitive Surgical recently reported revenue growth of 13% and 18.5% respectively, both beating expectations. Baxter shares have risen 11.3% over the past month, and the average analyst price target is $22.96 compared to the current share price of $24.50.
Yahoo Finance·28dRead more ▾
BAX
Baxter Q2 2026 earnings preview shows consensus EPS of $0.37
Baxter is scheduled to announce its second-quarter 2026 earnings results on Thursday, July 30th, before market open. The consensus earnings per share estimate stands at $0.37, representing a 37.3% decline year-over-year, while the consensus revenue estimate is $2.8 billion, down 0.4% from the prior year. Over the past two years, Baxter has beaten EPS estimates 63% of the time and revenue estimates 63% of the time. In the last three months, EPS estimates have seen zero upward revisions and ten downward revisions, while revenue estimates have seen two upward revisions and seven downward revisions.
Seeking Alpha·28dRead more ▾
BAX▼
Citi reveals most and least preferred stocks across four sectors for H2 2026
Citi has released its stock picks and pans for the second half of 2026, covering real estate, technology and communications, consumer, and healthcare sectors. The bank's year-end S&P 500 target of 8100 is driven by the AI-capex super cycle, according to strategist Scott Chronert. In real estate, most preferred REITs include WELL, PLD, and CPT, while BDN is least preferred. In technology and communications, favored names span sub-sectors such as internet with AMZN, GOOGL, and DASH, and semiconductors with AMD, TXN, and AMAT, while least preferred include OPTU, UNIT, and CCOI in communications infrastructure and QRVO, SWKS, and OLED in semiconductors. Consumer sector top picks feature CL, PG, and KO in beverages, and MCD, CMG, and BROS in restaurants, with KMB and CBRL among the least preferred. In healthcare, most preferred stocks include LLY, VRTX, and GILD in biotech and large cap pharma, and EW, ISRG, and SYK in medical technology, while BAX and XRAY are among the least preferred.
Seeking Alpha·52dRead more ▾
BAX▼
West Pharmaceutical Services Stock Surges 32.9% in 2026 on GLP-1 and Biologics Demand
West Pharmaceutical Services shares have risen 32.9% year to date in 2026, outperforming the industry's 30.3% decline and the S&P 500's 28.2% gain. The rally follows a strong first quarter where revenues grew 21% to $845 million and adjusted earnings per share surged 47%, prompting management to raise full-year guidance. Growth is being driven by accelerating demand for high-value product components used in GLP-1 obesity and diabetes therapies, which accounted for 10% of total company sales, as well as a 26% organic increase in biologics-related business. The company also reported a 66% year-over-year jump in projects tied to European Annex 1 sterile manufacturing regulations, expected to contribute approximately 200 basis points to 2026 revenues. While competition from Baxter International and Becton Dickinson remains intense, West Pharmaceutical's sharper focus on high-value pharmaceutical packaging and stronger margin expansion position it for continued momentum through the rest of the year.
Zacks Investment Research·54dRead more ▾
BAX▲
Baxter Publishes 2025 Sustainability Report with Refreshed Strategy and New Targets
Baxter International Inc. published its newly renamed 2025 Sustainability Report, introducing a refreshed sustainability strategy and new targets including Net-Zero greenhouse gas emissions across Scope 1 and Scope 2 by 2050 and 100% renewable electricity by 2040. The report, formerly called the Corporate Responsibility Report, highlights progress in 2025 such as more than $32 million in community contributions through strategic partnerships, product donations, and employee matching gifts. The company has established its first chief sustainability officer role and a new sustainability team to enhance coordination and accountability. Additional targets include having 80% of supplier spend in priority categories with suppliers that have science-based targets by 2030 and achieving 100,000 employee volunteer hours by 2031, alongside a previously established goal to invest $275 million by 2030 in underserved communities.
Business Wire·65dRead more ▾
MediThinQ and Synovis MCA Announce Global Distribution Deal for SHIYA 3D Surgical Platform
MediThinQ has entered into an exclusive multi-year global distribution agreement with Synovis Micro Companies Alliance, a subsidiary of Baxter International, to commercialize its SHIYA 3D surgical visualization platform. The partnership will enable a phased global rollout of SHIYA, leveraging Synovis MCA's three-decade expertise in microsurgery and its relationships with leading hospitals and reconstructive surgeons. SHIYA combines a high-resolution digital exoscope with up to 20x magnification and the proprietary wearable display SCOPEYE, allowing surgeons to operate without traditional eyepieces and supporting data capture for AI and analytics. The platform has been used in more than 100 procedures globally and is backed by peer-reviewed research, including a 2025 review in JPRAS Open and a 2026 paper in Plastic and Reconstructive Surgery highlighting its ergonomic and portability advantages. Financial terms of the agreement were not disclosed.
PR Newswire·69dRead more ▾
BAX
Baxter International Stock Falls 32.2% Over 52 Weeks, Underperforming S&P 500
Baxter International shares have declined 32.2% over the past 52 weeks, significantly underperforming the S&P 500 Index's 25.4% return over the same time frame. The stock is up 5.9% year-to-date, lagging the SPX's 9.6% gain, though it has risen 14.9% over the past three months, outpacing the index's 11.7% advance. Baxter's first-quarter 2026 revenue reached $2.7 billion, up about 3% year-over-year and beating analyst estimates, driven by a roughly 12% increase in international sales to $1.3 billion that offset a roughly 4% decline in U.S. sales to $1.4 billion. The company reaffirmed its full-year adjusted EPS guidance of $1.85 to $2.05. Analysts maintain a consensus Hold rating with a mean price target of $20.36, a marginal premium to current levels.
Barchart·70dRead more ▾